Brigit Biofarmaka Teknologi Tbk. vs Saraswanti Indoland Development Tbk. — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp236 (market cap 164.65B, 62.5K 24h volume), while Saraswanti Indoland Development Tbk. trades at Rp109 (market cap 608.51B, 16.35M 24h volume). The key difference: Saraswanti Indoland Development Tbk. is far larger — about 3.7× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Saraswanti Indoland Development Tbk. is more actively traded (16.35M versus 62.5K). Which is the better fit depends on your goals.
| OBAT | SWID | |
|---|---|---|
Market Cap | 164.65B | 608.51B |
Volume | 62.5K | 16.35M |
Lot | 625 | 163.51K |
Turnover | 15.03M | 1.79B |
Average Price | 240.55 | 109.4 |
Value | 15.03M | 1.79B |
Indicative Equilibrium Price | 238 | 109 |
Indicative Equilibrium Volume | 100 | 9.34K |
Trailing returns across standard periods
Latest headlines on both assets
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →PT Saraswanti Indoland Development Tbk ( The Company) was established on August 2, 2010 based on the Deed of Notary Ismaryani, SH, MKn. Number : 01. The deed of establishment of the Company was approved by the Minister of Law and Human Rights of the Republic of Indonesia number: AHU41610.AH.01.01.Tahun 2010. The Company started its commercial operations in 2011.
Read more on SWID →